Article: How Dendreon Is Proving Short Sellers Wrong

Article - Media

How Dendreon Is Proving Short Sellers Wrong

Gary Weiss

Seeking Alpha, 18 August 2009

In other words, Dendreon is not like the third-rate Internet retailer Overstock.com (NASDAQ:OSTK), whose wack-a-doo CEO Patrick Byrne has been weaving wild conspiracy theories over naked short selling for years, ever since it dawned on him that he simply does not know how to run a company. His talents, to the extent he has any, lie elsewhere (standup comedy?), but he has never eked out a profit for his company. His recent announcement of tiny fourth quarter profits was achieved by accounting gimmickry.

Read full article.

Article: Dendreon & Deceit: Jim Cramer, Pequot Capital

Article - Media, Publications

Dendreon & Deceit: Jim Cramer, Pequot Capital

Mark Mitchell, 19 July 2009

The CNBC “journalist” assured his viewers that the FDA advisory panel would vote that Dendreon’s treatment for prostate cancer was neither safe nor effective (notwithstanding the fact that the FDA had given the treatment “priority review” status because Provenge had shown strong trial results and was destined for critically ill patients).

Continue reading “Article: Dendreon & Deceit: Jim Cramer, Pequot Capital”